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Patients and Methods
A total of 31 consecutive patients with localized recurrent PCa undergoing salvage surgery with PSMA-targeted radioguided surgery using a 111 In-labelled PSMA ligand between April 2014 and July 2015 were retrospectively included in this study. The preoperative (interquartile range; range) median PSA level was 1.3 (0.57-2.53 ng/mL; 0.2-13.9 ng/mL). Results of ex vivo radioactivity rating (positive vs negative) of resected tissue specimens were compared with findings of postoperative histological analysis. Best PSA response without additional treatment was determined after 111 In-PSMA-RGS, and salvage-surgery-related postoperative complications and PCa-specific additional treatments were recorded.
Results
In 30/31 patients, 111 In-PSMA-RGS allowed intra-operative identification of metastatic lesions. In total, 145 surgical specimens were removed and 51 showed metastatic involvement at histological analysis. According to 111 In-PSMA-RGS ex vivo measurements, 48 specimens were correctly classified as metastatic and 87 as cancer-free, four were falsenegative and six were false-positive compared with histological evaluation. Follow-up information was available for 30/31 patients. PSA declines of >50% and >90% were observed in 23/ 30 patients and in 16/30 patients, respectively. In 18/30 patients, a PSA decline to <0.2 ng/mL was observed. In 10/30 patients further PCa-specific treatment was given after a median (range) of 125 (48-454) days post-111 In-PSMA-RGS. The remaining 20 patients remained treatment-free at a median (range) follow-up of 337 (81-591) days. Of 30 patients, 10 presented with surgery-related complications (Clavien-Dindo grade 1, n = 6, Clavien-Dindo grade 3b, n = 4).
Conclusion
111 In-PSMA-RGS proved to be of high value for intraoperative detection of even small metastatic lesions in patients with PCa scheduled for salvage lymphadenectomy. It allows the exact localization and resection of metastatic tissue during 111 In-PSMA-RGS and is therefore anticipated to have a beneficial influence on further disease progression; however, identification of suitable patients on the basis of PSMA-positron-emission tomography imaging as well as clinical variables is essential for satisfactory results to be obtained.
Introduction
Prostate cancer (PCa) is the most frequently occurring tumour in men worldwide and the development of tumour recurrence occurs in a significant number of patients after primary treatment [1] [2] [3] [4] . In these cases, early and sensitive detection of recurrent disease is crucial. Traditionally, in the setting of local tumour recurrence after radical prostatectomy or radiotherapy, salvage radiotherapy or surgery represents a potentially curative therapy option, while patients with metastatic spread are usually given androgen deprivation therapy, regardless of the exact site and extent of tumour recurrence, serving only as palliative therapy option [5] . In patients with good performance status and only minimal or localized tumour burden, however, individual local salvage concepts might represent a promising alternative, influencing progression-free survival positively [6, 7] . Local treatment strategies, such as salvage lymphadenectomy or stereotactic radiation, are therefore of increasing interest. A prerequisite for these salvage concepts is reliable and early detection of tumour recurrence. In this setting, morphological imaging procedures, such as CT or MRI, as well as functional positron-emission tomography (PET) imaging using radiolabelled choline derivatives, have severe limitations and often underestimate the extent of metastatic spread [8, 9] .
Recently, 68 Ga-HBED-CC-prostate-specific membrane antigen (PSMA) and 68 Ga-PSMA-I&T-based PET hybrid imaging has been introduced, resulting in increased detection rates in patients with recurrent PCa after radical prostatectomy, especially at low PSA values [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Pooled data from a recently published meta-analysis indicate favourable sensitivity and specificity profiles compared with cholinebased PET imaging techniques, with pre-PET PSA predicting the risk of positive 68 Ga-HBED-CC-PSMA PET [20] . With the advent of PSMA-targeted PET and the visualization of even small soft tissue metastases (mainly lymph node metastases) salvage surgery is of increasing interest in recurrent PCa. Intra-operative detection and resection of these small metastatic sites might be problematic, however, because of their inconspicuous morphology and/or atypical localization. Recently, we described a novel method for detecting metastatic PCa lesions intra-operatively after i.v. administration of 111 In-labelled PSMA-I&T and subsequent surgery using a gamma probe [21] . In that preliminary study, PSMA-radioguided surgery (PSMA-RGS) using 111 In-labelled PSMA-I&T proved to be of high value for intra-operative detection of small unobtrusive and/or atypically located metastatic lymph nodes.
The aim of the present study was to evaluate the use of 111 Inlabelled PSMA-I&T radioguided surgery ( In-PSMA-RGS was evaluated with respect to postoperative PSA responses, PCa-specific treatment-free survival as well as postoperative complication rates.
Materials and Methods

Patients
The present retrospective analysis included 31 consecutive patients (April 2014 to July 2015) with a rising PSA level to ≥0.2 ng/mL after primary curative therapy (radical prostatectomy, n = 29; radiation therapy, n = 1; high-intensity focused ultrasonography, n = 1) and 68 In-labelled PSMA-I&T at a mean AE SD (range) of 22.9 AE 3.0 (16.7-28.0) h before 111 In-PSMA-RGS [22] . Intra-operatively, metastatic PCa lesions were tracked using a gamma probe (Crystal Probe CXS-SG603; Crystal Photonics, Berlin, Germany) with acoustic feedback. Resected tissue was measured ex vivo (rating positive or negative in comparison to background). A count rate at least double the background reference was judged as being radioactivity-positive. Histological evaluation was performed in separate fractions to ensure exact matching. Besides conventional haematoxylin and eosin staining, histological analysis also included PSMA immunohistochemistry.
Patient Follow-Up
Follow-up of all patients was carried out on a regular basis. PSA values after 111 In-PSMA-RGS were recorded and best PSA response without any additional PCa-specific treatment was determined. Furthermore, salvage surgery-related postoperative complications according to the Clavien-Dindo classification system and PCa-specific additional treatments were noted. Minimal follow-up was 2.7 months.
Statistical Analysis
All statistical analyses were performed using MEDCALC software (version 13.2.0, 2014; MEDCALC, Ostend, Belgium), SPSS (version 23, IBM), or R version 3.3.0 (R Foundation for Statistical Computing). For description of quantitative data mean values, median, interquartile ranges (IQRs) and/or ranges are presented, as appropriate. Absolute and relative frequencies are given for categorical data. Diagnostic accuracy is described using sensitivity, specificity and accuracy rates. To account for within-subject correlation, as multiple specimens were considered for each patient, logistic generalized estimating equation models [23] were fitted to the data. For estimation of sensitivities and corresponding CIs an intercept-only logistic generalized estimating equation model was used. The test result was used as the dependent variable, and only patients with a positive histopathological result were considered [24] . To derive estimates for the specificities, a variable indicating whether a negative test result was observed was used as the dependent variable and only patients with a negative histopathological result were included. For estimation of positive and negative predictive values, the independent and dependent variables were used in a vice versa manner. Accuracy was estimated in an intercept-only model with a dependent variable that indicated whether the test result and the result of the histopathological assessment agreed. For all generalized estimating equation models an independent correlation structure was assumed. Waterfall plots were used to show best PSA responses after 111 In-PSMA-RGS. The distribution of treatment-free survival times after 111 In-PSMA-RGS was estimated using the Kaplan-Meier method.
Results
In-PSMA-RGS for Intra-operative Lesion Detection
The mean and median (range) numbers of removed tissue specimens were 4.7 and 4.0 (1-18), respectively. Duration of surgery was a median (range) of 123 (78-218) min. In 30/31 patients, 111 In-PSMA-RGS allowed intra-operative identification of the PET-positive lesions. In one patient exhibiting a preoperative PSA of 0.45 ng/mL, identification of a small suspicious lesion in the deep internal region was not successful. On follow-up PSMA-PET imaging the lesion was still present. Compared with 68 Ga-HBED-CC-PSMA PET, 111 In-PSMA-RGS was able to detect five additional suspicious specimens in 3/31 patients. Corresponding histological analysis revealed seven small lymph node metastases in these specimens.
In total, 145 histological specimens were measured intraoperatively with 48 of them classified as positive according to both gamma probe and histopathology and 87 of them negative with gamma probe and histopathology. Six falsepositive lesions (positive with gamma probe and unobtrusive in histopathology) and four false-negative lesions were detected (positive histopathological result and unsuspicious after measurement with gamma probe). Ex vivo measurements with gamma probe correlated well with histology, resulting in a sensitivity, specificity and accuracy of 92.3% (95% CI 83. In-PSMA-RGS without further prostate-specific therapy of the available 30 patients are shown in Fig. 3. A total of 10/30 patients (33%) received further PCa-specific treatment at a median (range) of 125 (48-454) days after 111 In-PSMA-RGS, while the remaining 20 patients remained treatment-free at a median (range) follow-up of 337 (81-591) days. Of those 10 patients receiving further therapy, three patients received only radiation therapy of the pelvis, one patient only androgen deprivation therapy and the remaining six patients were treated with combined radiation and androgen deprivation therapy. Comparison of clinical characteristics in patients with or without further PCa-specific As the number of patients in this described cohort was limited, no statistical analysis was performed to determine the possible influence of these variables on treatment-free survival. The duration of treatment-free survival after 111 In-PSMA-RGS is shown in Fig. 4 .
Postoperative Complications and Re-interventions
After the application of 111 In-labelled PSMA-I&T, no adverse reaction was observed. In 20/30 patients (67%) no complications related to the salvage surgery procedure were observed. As mentioned above, one patient developed a pulmonary embolism 2 months after surgery. The relationship to the salvage surgery procedure in this case cannot be determined, as this patient had been discharged without any sequelae from the hospital >6 weeks before his pulmonary embolism. A total of 10 patients (33%) presented with complications related to the surgical procedure (Table 3) . Six patients presented with grade 1 postoperative complications, while four patients needed further re-interventions (grade 3b).
Discussion
The results of the present analysis indicate that 111 In-PSMA-RGS is of high value for the intra-operative detection of small soft tissue metastases in patients with recurrent PCa scheduled for salvage surgery, as it allows detection of PSMAexpressing PCa deposits intra-operatively with a high sensitivity (92.3%) and specificity (93.5%). With intraoperative use of the gamma probe all PSMA-positive lesions 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 PSA change fom baseline (%) Best PSA response Fig. 3 Best PSA response in patients undergoing 111 In-labelled prostate-specific membrane antigen radioguided surgery. In-PSMA-RGS Mean (IQR; range) PSA, ng/mL 2.7 (0.52-2.2; 0.3-13.9) Ga-HBED-CC-PSMA PET could be detected (except one that was missed in the internal iliac artery region that was confirmed on follow-up imaging). Intra-operative measurements have been found to be even more sensitive, however, as a result of reduced lesion-todetector distance; compared with preoperative 68 Ga-HBED-CC-PSMA PET, five more lesions in three patients were detected during 111 In-PSMA-RGS. In these three patients, the time interval between 68 Ga-HBED-CC-PSMA PET and 111 In-PSMA-RGS ranged between 50 and 65 days, therefore, interval progression seems unlikely.
In the present analysis, a total of six false-positive lesions were identified in three patients; however, it should be noted that five of those six false-positive lesions showed only an activity count rate, while one lesion showed a moderate signal when measured with the gamma probe. Furthermore, one single false-negative lymph node specimen was found in four different patients (micrometastases up to 4 mm).
When considering the individual concept of salvage surgery in patients with PCa, careful patient selection is critical in order to achieve acceptable cancer control rates and to avoid unnecessary morbidity. Obviously, a positive [
68 Ga]HBED-CC-PSMA-PET scan represents the primary basis of eligibility for 111 In-PSMA-RGS; however, several clinical variables should also be taken into account. Recently, several factors identifying suitable candidates for salvage lymphadenectomy have been defined. Rigatti et al. [25] observed that the 5-year clinical recurrence-free survival was higher for patients with preoperative PSA values < 4 ng/mL compared with patients with a PSA ≥4 ng/mL (48 vs 13%). In the present study, 85% of patients (17/20) receiving no further therapy presented with a PSA value of < 4 ng/mL. Additionally, we observed that the mean PSA level at the time of 111 In-PSMA-RGS was considerably higher in patients receiving additional PCaspecific treatment (mean PSA 2.7 ng/mL) compared with those without any additional treatment (mean PSA 1.8 ng/mL) during clinical follow-up after PSMA-RGS.
Furthermore, Rigatti et al. [25] observed that the 5-year clinical recurrence-free survival was lower for patients with positive lymph nodes in the retroperitoneum compared with patients in whom positive lymph nodes were detected in the pelvis only (11 vs 53%; P < 0.001). In the present analysis only three patients presented with lymph node metastases in the retroperitoneum (one patient with additional PCa-specific therapy and two without further therapy), and therefore no conclusions can be drawn from the present data regarding the influence of metastasis localization as a predictor of clinical progression.
Jilg et al. [26] found a Gleason score of 8-10 to be an independent predictor of clinical progression. This is in concordance with our results where 5/10 patients with Gleason scores of 8-10 received further PCa-specific therapy while only 1/5 patients with a Gleason score ≤6 and 3/14 patients with a Gleason score of 7 received additional PCa-specific therapy.
Several postoperative factors including complete biochemical response and number of positive lymph nodes at salvage lymphadenectomy are established as independent predictors of clinical progression as well. The results of the present analysis show that most of the patients without further PCa-specific therapy presented with a complete biochemical response (75%), and the mean number of soft tissue metastases found in patients receiving further PCa-specific Treatment-free survival (%) Fig. 4 Prostate cancer-specific treatment-free survival after 111 In-labelled prostate-specific membrane antigen radioguided surgery. Table 3 Complications related to salvage surgery according to the Clavien-Dindo classification system (n = 30). In-PSMA-RGS whether adjuvant radiotherapy with or without short-term androgen deprivation therapy has a positive influence on the relapse-free survival of patients undergoing salvage lymphadenectomy as well.
The potential morbidity associated with these salvage procedures should also be considered. In the present patient cohort, 33% of the patients presented with surgery-related complications, with most of them rated grade 1 (60%) as defined by the Clavien-Dindo classification system. This is consistent with the results in the literature, in which the most frequently reported complications were also grade 1, such as lymphorrhea (21%) and fever (25-30%) or prolonged ileus (20%, grade 2) [25, 28] . High grade (Clavien 3b) complications were only rarely observed, consisting, for example, of ureteric injury in one case and the necessity for surgical reinterventions in two cases [25, 26] . In the present series, four grade 3b complications were noted. Two patients developed a pararectal abcess requiring re-operation and a transient protective stoma, while one patient sustained an injury to the ureter requiring psoas hitch reconstruction and one patient developed septic hydronephrosis that was treated with JJ stent insertion. These higher complication rates of salvage surgery procedures compared with the primary surgery setting are attributed not only to fibrotic changes after previous surgery and radiotherapy, but also reflect the often challenging location of recurrent PCa lesions.
In summary,
111
In-PSMA-RGS proved to be of high value for the intra-operative detection of small soft tissue metastases in patients scheduled for salvage lymphadenectomy. It might have a beneficial influence on further disease progression by generally delaying the need for further systemic treatment and, in a subset of patients, holds promise for achieving permanent cure. Identification of suitable patients on the basis of PSMA-PET imaging as well as according to clinical variables is critical to obtain satisfactory results; however, larger patient cohorts as well as more robust follow-up data are needed to determine which patients will benefit most from salvage surgery procedures and PSMA-targeted RGS.
